Thermo Fisher Scientific Heats Up Q3 2026 with Record-Breaking Growth

Thermo Fisher Scientific, a global leader in scientific instrumentation and software, has reported another impressive quarter with outstanding financial performance. The company's Chairman and Chief Executive Officer, Marc Casper, showcased the strength of its growth strategy during the Q3 2026 conference call.

The company delivered an excellent quarter, with revenue growing 9% to $12.14 billion and adjusted operating income increasing by 15% to $2.97 billion. Adjusted operating margin expanded by a significant 120 basis points to 24.5%. These results were driven by strong growth across various end markets, including pharma and biotech, industrial and applied, and diagnostics and healthcare.

In the pharma and biotech segment, Thermo Fisher delivered high single-digit growth during the quarter, led by its Pharma Services business and research and safety market channel. The company also experienced strong growth in its clinical research business. In contrast, revenue was flat in the academic and government segment, although the chromatography and mass spectrometry business showed good performance.

The industrial and applied segment saw high single-digit growth during the quarter, with the electron microscopy business and research and safety market channel leading the charge. The diagnostics and healthcare segment experienced low single-digit growth, driven by strong performance in the transplant diagnostics business.

Thermo Fisher's growth strategy consists of three pillars: high-impact innovation, trusted partner status with customers, and an unparalleled commercial engine. During Q3 2026, the company continued to execute well on this strategy, launching new technologies that enhance industry leadership and help customers gain deeper scientific insights, boost productivity, and accelerate innovation.

The launch of the Thermo Scientific Orbitrap Isora Mass Spectrometer, the first Orbitrap system for isotope ratio analysis, is a prime example of this high-impact innovation. This cutting-edge technology strengthens Thermo Fisher's industry leadership in chromatography and mass spectrometry and helps customers gain deeper scientific insights.

With its proven growth strategy and strong execution, Thermo Fisher Scientific is well-positioned to deliver an excellent 2026. The company continues to drive long-term value creation for all stakeholders and build a brighter future for itself. As Marc Casper emphasized during the conference call, Thermo Fisher's PPI Business System enables outstanding execution across the company, setting it up for continued success.

The company's financial performance was also impressive, with adjusted EPS growing by 15% to $6.68 per share. This growth demonstrates the company's ability to deliver value to its stakeholders and maintain its position as a leader in the scientific instrumentation and software industry.

As Thermo Fisher Scientific continues to execute on its growth strategy, investors and analysts are taking note of the company's strong performance. With its commitment to innovation, trusted partner status with customers, and commercial engine, Thermo Fisher is poised for continued success in 2026 and beyond.